Last reviewed · How we verify
Testosterone replacement
At a glance
| Generic name | Testosterone replacement |
|---|---|
| Also known as | Testosterone Undecylate (Nebido) |
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism (PHASE2)
- State of Hormones Impact Nociceptive Expression
- Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance (PHASE4)
- 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism (PHASE3)
- Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone (PHASE1)
- Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance (PHASE4)
- Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version (PHASE4)
- Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |